Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOAD Regimen in Relapsed/Refractory ALL
NCT00905034Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2009
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies, Therapeutic Enzymes, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of methotrexate, vincristine, pegaspargase, dexamethasone, rituximab in acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), Burkitt lymphoma (BL), lymphoblastic lymphoma (LL), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2009; status: completed.
02
Drugs
methotrexatevincristinepegaspargasedexamethasonerituximab
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)Burkitt lymphoma (BL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00905034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00905034.